Investigational Drug for HER2 Tumors, Including Breast Cancer, Now Part of Alliance with Mersana, Takeda
Breast Cancer News, News
Takeda Pharmaceutical Company and Mersana Therapeutics have announced a new alliance that grants Takeda rights over XMT-1522, the lead product candidate of Mersana, outside the U.S. and Canada. The agreement also ... Read more